Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1991005801) DOPAMINE RELEASING PROTEIN
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/005801 International Application No.: PCT/US1990/005860
Publication Date: 02.05.1991 International Filing Date: 12.10.1990
Chapter 2 Demand Filed: 02.05.1991
IPC:
A61K 38/00 (2006.01) ,C07K 14/575 (2006.01) ,C07K 16/26 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
575
Hormones
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
26
against hormones
Applicants:
CHIRON CORPORATION [US/US]; 4560 Horton Street Emeryville, CA 94608, US
Inventors:
RAMIREZ, Victor, Domingo; US
MARCUS, Frank; US
Agent:
CIOTTI, Thomas, E. ; Irell & Manella 545 Middlefield Road Suite 200 Menlo Park, CA 94025, US
Priority Data:
420,83012.10.1989US
Title (EN) DOPAMINE RELEASING PROTEIN
(FR) PROTEINE LIBERANT DE LA DOPAMINE
Abstract:
(EN) Dopamine releasing protein (DARP) is a protein which stimulates release of dopamine from dopaminergic neurons, and is effective at extremely low concentrations. DARP is useful for stimulating vertebrate nervous systems, and for treatment of Parkinson's disease. Antibodies to DARP are useful for inhibiting dopamine release, and for quantifying the concentration of DARP in samples.
(FR) La protéine libérant de la dopamine (DARP) est une protéine stimulant la libération de dopamine à partir de neurones dopaminergiques, et est efficace à des concentrations extrêmement faibles. On utilise la DARP afin de stimuler les systèmes nerveux des vertébrés, et dans le traitement de la maladie de Parkinson. Les anticorps contre la DARP sont utiles pour inhiber la libération de dopamine, et afin de quantifier la concentration de DARP dans des échantillons.
Designated States: CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0495893US5330895CA2065442